Jonathan Kruh, MD
Ophthalmology · Elmhurst, NYNPI 1801191184
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 291 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 32.9% of the total. 2025 is the largest year on record at $2,447, 3.0 times the $804 reported in 2019.
Across 291 payments — averaging $33.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$3K
- Glaukos Corporation$922
- Sun Pharmaceutical Industries Inc.$727
- Alcon$646
- Biotissue Holdings Inc.$559
- Aerie Pharmaceuticals, Inc.$525
- plus $3K from 20 others
What the payments were for
- Food & beverage$9,38897%
- Education$3043%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 80 | $3,184 |
| Glaukos Corporation | 14 | $922 |
| Sun Pharmaceutical Industries Inc. | 32 | $727 |
| Alcon | 18 | $646 |
| Biotissue Holdings Inc. | 21 | $559 |
| Aerie Pharmaceuticals, Inc. | 5 | $525 |
| Bausch & Lomb Americas Inc. | 16 | $325 |
| Tarsus Pharmaceuticals, Inc. | 14 | $320 |
| Oyster Point Pharma, Inc. | 13 | $317 |
| AbbVie(2 entities) | 12 | $304 |
| Harrow Eye, LLC | 11 | $271 |
| Dompe US, Inc. | 10 | $249 |
| Rxsight Inc | 3 | $198 |
| Kala Pharmaceuticals, Inc. | 9 | $191 |
| Amgen(2 entities) | 6 | $135 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $132 |
| Avedro Inc. | 1 | $126 |
| Shire North American Group Inc | 1 | $121 |
| Thea Pharma Inc. | 4 | $98 |
| Novartis | 3 | $69 |
| Eyepoint US, Inc. | 3 | $65 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $47 |
| Beaver-visitec International, Inc. | 1 | $43 |
| Eyevance Pharmaceuticals LLC | 2 | $41 |
| NEW World Medical,inc. | 2 | $40 |
| Carl Zeiss Meditec Cataract Technology Inc. | 1 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,691 in reported general payments places this provider in the 85th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 117 | $123,341 |
| Humira(Cf) PenAdalimumab | 15 | $98,936 |
| CequaCyclosporine | 98 | $71,153 |
| VyzultaLatanoprostene Bunod | 76 | $30,247 |
| RhopressaNetarsudil Mesylate | 63 | $24,033 |
| RocklatanNetarsudil Mesylat/Latanoprost | 46 | $22,665 |
| TyrvayaVarenicline Tartrate | 27 | $21,490 |
| Prednisolone Acetate | 389 | $16,160 |
| LumiganBimatoprost | 32 | $12,510 |
| VevyeCyclosporine | 12 | $11,764 |
| Cyclosporine | 23 | $10,376 |
| ZirganGanciclovir | 14 | $6,591 |
| Bromfenac Sodium | 34 | $5,378 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $5,302 |
| FlarexFluorometholone Acetate | 33 | $4,910 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $304 | $141,153168 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $727 | $71,15398 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $525 | $46,697109 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Zirgan | $325 | $36,83990 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $317 | $21,49027 claims |
| Harrow Eye, LLCVevye | $271 | $11,76412 claims |
| Eyevance Pharmaceuticals LLCFlarex, Tobradex St | $41 | $7,67045 claims |
| Thea Pharma Inc.Iyuzeh | $98 | $4,64216 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $47 | $3,82222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Elmhurst
- David RubaltelliBrooklyn$8.9M
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Eric DonnenfeldGarden City$1.4M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- David KleinmanRochester$730K
- Jonathan JonischGreat Neck$726K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.